BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36525269)

  • 1. Relevance of Molecular Profiling in Patients With Low-Grade Endometrial Cancer.
    Vrede SW; Kasius J; Bulten J; Teerenstra S; Huvila J; Colas E; Gil-Moreno A; Boll D; Vos MC; van Altena AM; Asberger J; Sweegers S; van Weelden WJ; van der Putten LJM; Amant F; Visser NCM; Snijders MPLM; Küsters-Vandevelde HVN; Kruitwagen R; Matias-Guiu X; Weinberger V; Reijnen C; Pijnenborg JMA
    JAMA Netw Open; 2022 Dec; 5(12):e2247372. PubMed ID: 36525269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
    Willvonseder B; Stögbauer F; Steiger K; Jesinghaus M; Kuhn PH; Brambs C; Engel J; Bronger H; Schmidt GP; Haller B; Weichert W; Keller G; Noske A; Pfarr N; Boxberg M
    Cancer Immunol Immunother; 2021 Jun; 70(6):1679-1689. PubMed ID: 33340331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma.
    Travaglino A; Raffone A; Mollo A; Borrelli G; Alfano P; Zannoni GF; Insabato L; Zullo F
    Arch Gynecol Obstet; 2020 May; 301(5):1117-1125. PubMed ID: 32253551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
    Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
    Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The Cancer Genome Atlas-like Prognostic Subgroups.
    Irshaid L; Costigan DC; Dong F; Matulonis UA; Nucci MR; Kolin DL
    Mod Pathol; 2023 May; 36(5):100123. PubMed ID: 36857998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Significance of International Federation of Gynecology and Obstetrics Grading in Microsatellite Instability-High and POLE-Mutant Endometrioid Endometrial Carcinoma.
    Kertowidjojo E; Momeni-Boroujeni A; Rios-Doria E; Abu-Rustum N; Soslow RA
    Mod Pathol; 2023 Sep; 36(9):100234. PubMed ID: 37268062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application and clinical significance of TCGA molecular classification in endometrial cancer].
    Zhao LY; Dai YB; Li LW; Wang ZQ; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2021 Oct; 56(10):697-704. PubMed ID: 34823319
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer.
    AlHilli MM; Mariani A; Bakkum-Gamez JN; Dowdy SC; Weaver AL; Peethambaram PP; Keeney GL; Cliby WA; Podratz KC
    Gynecol Oncol; 2014 Jun; 133(3):485-93. PubMed ID: 24690476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
    Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
    PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging.
    Cusimano MC; Vicus D; Pulman K; Maganti M; Bernardini MQ; Bouchard-Fortier G; Laframboise S; May T; Hogen LF; Covens AL; Gien LT; Kupets R; Rouzbahman M; Clarke BA; Mirkovic J; Cesari M; Turashvili G; Zia A; Ene GEV; Ferguson SE
    JAMA Surg; 2021 Feb; 156(2):157-164. PubMed ID: 33175109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical application of adult comorbidity evaluation-27 in endometrial cancer].
    Tian WY; Wang YM; Yan Y; Gao JP; Sun DD; Jiang S; Sheng Y; Teng F; Xue FX
    Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):810-817. PubMed ID: 27916063
    [No Abstract]   [Full Text] [Related]  

  • 12. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
    Wu Q; Zhang N; Xie X
    BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death.
    Jamieson A; Huvila J; Chiu D; Thompson EF; Scott S; Salvador S; Vicus D; Helpman L; Gotlieb W; Kean S; Samouelian V; Köbel M; Kinloch M; Parra-Harran C; Offman S; Grondin K; Irving J; Lum A; Senz J; Leung S; McConechy MK; Plante M; Kommoss S; Huntsman DG; Talhouk A; Gilks CB; McAlpine JN
    Mod Pathol; 2023 Apr; 36(4):100085. PubMed ID: 36788084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer: A Taiwanese Gynecology Oncology Group (TGOG-2005) Retrospective Cohort Study (A STROBE-Compliant Article).
    Chen JR; Chang TC; Fu HC; Lau HY; Chen IH; Ke YM; Liang YL; Chiang AJ; Huang CY; Chen YC; Hong MK; Wang YC; Huang KF; Hsiao SM; Wang PH
    Medicine (Baltimore); 2016 Apr; 95(15):e3330. PubMed ID: 27082583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of
    Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
    Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
    Bildrici K; Tel N; Ozalp SS; Yalcin OT; Yilmaz V
    Eur J Gynaecol Oncol; 2002; 23(6):540-4. PubMed ID: 12556100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity and Lymphovascular Invasion in Women with Uterine Endometrioid Carcinoma.
    Kamal M; Burmeister C; Zhang Z; Munkarah A; Elshaikh MA
    Anticancer Res; 2015 Jul; 35(7):4053-7. PubMed ID: 26124354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical patterns and genomic profiling of recurrent 'ultra-low risk' endometrial cancer.
    Stasenko M; Feit N; Lee SSK; Shepherd C; Soslow RA; Cadoo KA; Alektiar K; Da Silva EM; Martins Sebastião AP; Leitao MM; Gardner G; Selenica P; Abu-Rustum NR; Weigelt B; Mueller JJ
    Int J Gynecol Cancer; 2020 Jun; 30(6):717-723. PubMed ID: 32376737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FIGO Versus Silverberg Grading Systems in Ovarian Endometrioid Carcinoma: A Comparative Prognostic Analysis.
    Parra-Herran C; Bassiouny D; Vicus D; Olkhov-Mitsel E; Cesari M; Ismiil N; Nofech-Mozes S
    Am J Surg Pathol; 2019 Feb; 43(2):161-167. PubMed ID: 30212391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer.
    Siegenthaler F; Epstein E; Büchi CA; Gmür A; Saner FACM; Rau TT; Carlson JW; Mueller MD; Imboden S
    Int J Gynecol Cancer; 2023 Nov; 33(11):1702-1707. PubMed ID: 37666529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.